Saltar al contenido
Merck

L4144

Lectina de Phaseolus vulgaris (frijol rojo)

Leucoagglutinin PHA-L, lyophilized powder, BioReagent, suitable for cell culture

Sinónimos:

Aglutinina de Phaseolus vulgaris, PHA

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

UNSPSC Code:
12352202
EC Number:
232-718-7
NACRES:
NA.32
Form:
lyophilized powder
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


Quality Level

product line

BioReagent

form

lyophilized powder

potency

erythroagglutination activity (Does not agglutinate a 2% suspension of human erythrocytes at 250 μg lectin/ml.), ≤1.0 μg per mL leucoagglutination activity, ≤5 μg per mL mitogenic activity (Bromdeoxyuridine incorporation in human peripheral blood mononuclear cells)

technique(s)

cell culture | mammalian: suitable

impurities

salt, free

solubility

DPBS: 5 mg/mL, slightly hazy, colorless

suitability

leucocyte agglutination activity tested

storage temp.

2-8°C

General description

Lectins are carbohydrate-binding proteins, which contains four subunits with a molecular weight of 125 kDa. Leucoagglutinin PHA-L is a plant lectin, which is transported by the neurons in the central nervous system.

Application

Lectin from Phaseolus vulgaris (red kidney bean) has been used:
  • it has been used as a positive control to treat cells
  • to stimulate cell culture for the analysis of lymphocyte proliferation
  • to stimulate T cells

Biochem/physiol Actions

Lectin agglutinates cells and precipitates polysaccharides and glycoproteins. It is associated with toxic allergens and hemagglutinins. Lectin exhibits anti-cancer, anti-human immunodeficiency virus (anti-HIV) and anti-microbial infection properties. Lectin inhibits mucosal atrophy, lowers type 2 diabetes and obesity, enhances nutrient absorption and regulates drug targeting.
La PHA consta de dos especies moleculares, la eritroaglutinina (PHA-E), que tiene poca actividad mitógena y elevada actividad de eritroaglutinina, y la leoucoaglutinina (PHA-L), que tiene elevada actividad mitógena y leoucoaglutinante, pero muy baja actividad eritroaglutininante
La PHA-E no es específica de grupo sanguíneo, pero la aglutinación puede ser inhibida por ciertos oligosacáridos. La PHA-P es la forma proteica de la PHA antes de la separación y la purificación de la eritroaglutinina y la leoucoaglutinina. La PHA-M es la forma mucoproteínica. Los conjugados se preparan a partir de las correspondientes lectinas purificadas.

Analysis Note

Agglutination activity is expressed in μg/ml and is determined from serial dilutions of a 1 mg/ml solution. This activity is the lowest concentration to agglutinate a suspension of either human erythrocytes (2% in phosphate buffered saline, pH 6.8) or human leukocytes (107 per mL in saline) after 1 hr incubation at 25 °C.


Still not finding the right product?


Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos


Contenido relacionado

Instructions


SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak, et al.
Annals of the Rheumatic Diseases (2021)
Patricia Kaaijk et al.
Scientific reports, 11(1), 13664-13664 (2021-07-03)
Mumps is nowadays re-emerging despite vaccination. The contribution of T cell immunity to protection against mumps has not been clearly defined. Previously, we described a set of 41 peptides that were eluted from human leukocyte antigen (HLA) class I molecules
Haifeng Huang et al.
Acta pharmaceutica Sinica. B, 10(7), 1321-1330 (2020-09-03)
JS001 (toripalimab) is a humanized IgG monoclonal antibody which strongly inhibits programmed cell death protein 1 (PD1). In this study, we used a different iodine isotype (nat/124/125I) to label JS001 probes to target the human PD1 (hPD1) antigen. In vitro